Evaluation of the Protective Immunity of a Novel Subunit Fusion Vaccine in a Murine Model of Systemic MRSA Infection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Dec 11

PMID 24324681

Citations 18

Authors

Qian-Fei Zuo

Liu-Yang Yang

Qiang Feng

Dong-Shui Lu

Yan-Dong Dong

Chang-Zhi Cai

Yi Wu

Ying Guo

Jiang Gu

Hao Zeng

Quan-Ming Zou

Affiliations

Soon will be listed here.

Abstract

Staphylococcus aureus is a common commensal organism in humans and a major cause of bacteremia and hospital acquired infection. Because of the spread of strains resistant to antibiotics, these infections are becoming more difficult to treat. Therefore, exploration of anti-staphylococcal vaccines is currently a high priority. Iron surface determinant B (IsdB) is an iron-regulated cell wall-anchored surface protein of S. aureus. Alpha-toxin (Hla) is a secreted cytolytic pore-forming toxin. Previous studies reported that immunization with IsdB or Hla protected animals against S. aureus infection. To develop a broadly protective vaccine, we constructed chimeric vaccines based on IsdB and Hla. Immunization with the chimeric bivalent vaccine induced strong antibody and T cell responses. When the protective efficacy of the chimeric bivalent vaccine was compared to that of individual proteins in a murine model of systemic S. aureus infection, the bivalent vaccine showed a stronger protective immune response than the individual proteins (IsdB or Hla). Based on the results presented here, the chimeric bivalent vaccine affords higher levels of protection against S. aureus and has potential as a more effective candidate vaccine.

Citing Articles

Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas.

Justiz-Vaillant A, Gopaul D, Soodeen S, Unakal C, Thompson R, Pooransingh S Microorganisms. 2024; 12(8).

PMID: 39203514 PMC: 11357253. DOI: 10.3390/microorganisms12081672.

Story of Pore-Forming Proteins from Deadly Disease-Causing Agents to Modern Applications with Evolutionary Significance.

Gupta L, Molla J, Prabhu A Mol Biotechnol. 2023; 66(6):1327-1356.

PMID: 37294530 DOI: 10.1007/s12033-023-00776-1.

Isovitexin Protects Mice from Methicillin-Resistant -Induced Pneumonia by Targeting Sortase A.

Tian L, Wu X, Yu H, Yang F, Sun J, Zhou T J Microbiol Biotechnol. 2022; 32(10):1284-1291.

PMID: 36224754 PMC: 9668100. DOI: 10.4014/jmb.2206.06007.

Immunopotentiating properties of chimeric OprF-OprI-PopB protein against PAO1 in the infected burned rat model.

Sabzehali F, Goudarzi H, Goudarzi M, Chirani A, Yoosefi Izad M Iran J Basic Med Sci. 2022; 25(3):276-285.

PMID: 35656187 PMC: 9148398. DOI: 10.22038/IJBMS.2022.61448.13595.

Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection.

Yang L, Wei C, Yang Y, Tong Y, Yang S, Peng L RSC Adv. 2022; 8(19):10425-10436.

PMID: 35540467 PMC: 9078882. DOI: 10.1039/c8ra00154e.

References

Stranger-Jones Y, Bae T, Schneewind O . Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A. 2006; 103(45):16942-7. PMC: 1636558. DOI: 10.1073/pnas.0606863103. View

Zhao Y, Nilsson I, Tarkowski A . The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology. 1998; 93(1):80-5. PMC: 1364109. DOI: 10.1046/j.1365-2567.1998.00407.x. View

Mazmanian S, Ton-That H, Su K, Schneewind O . An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc Natl Acad Sci U S A. 2002; 99(4):2293-8. PMC: 122358. DOI: 10.1073/pnas.032523999. View

Diekema D, Pfaller M, Schmitz F, Smayevsky J, Bell J, Jones R . Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial.... Clin Infect Dis. 2001; 32 Suppl 2:S114-32. DOI: 10.1086/320184. View

Valeva A, Weisser A, Walker B, Kehoe M, Bayley H, Bhakdi S . Molecular architecture of a toxin pore: a 15-residue sequence lines the transmembrane channel of staphylococcal alpha-toxin. EMBO J. 1996; 15(8):1857-64. PMC: 450103. View

Fattom A, Schneerson R, Szu S, Vann W, Shiloach J, KARAKAWA W . Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990; 58(7):2367-74. PMC: 258821. DOI: 10.1128/iai.58.7.2367-2374.1990. View

Proctor R . Is there a future for a Staphylococcus aureus vaccine?. Vaccine. 2011; 30(19):2921-7. DOI: 10.1016/j.vaccine.2011.11.006. View

Schaffer A, Solinga R, Cocchiaro J, Portoles M, Kiser K, Risley A . Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun. 2006; 74(4):2145-53. PMC: 1418917. DOI: 10.1128/IAI.74.4.2145-2153.2006. View

Foster T . Immune evasion by staphylococci. Nat Rev Microbiol. 2005; 3(12):948-58. DOI: 10.1038/nrmicro1289. View

10.

Joshi A, Pancari G, Cope L, Bowman E, Cua D, Proctor R . Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother. 2012; 8(3):336-46. PMC: 3426080. DOI: 10.4161/hv.18946. View

11.

Fowler Jr V, Miro J, Hoen B, Cabell C, Abrutyn E, Rubinstein E . Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005; 293(24):3012-21. DOI: 10.1001/jama.293.24.3012. View

12.

Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S . A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies. 2010; 19(4):113-28. DOI: 10.3233/HAB-2010-0235. View

13.

Verkaik N, van Wamel W, van Belkum A . Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy. 2011; 3(9):1063-73. DOI: 10.2217/imt.11.84. View

14.

Mamo W, Jonsson P, Flock J, Lindberg M, Muller H, Wadstrom T . Vaccination against Staphylococcus aureus mastitis: immunological response of mice vaccinated with fibronectin-binding protein (FnBP-A) to challenge with S. aureus. Vaccine. 1994; 12(11):988-92. DOI: 10.1016/0264-410x(94)90333-6. View

15.

Spellberg B, Daum R . Development of a vaccine against Staphylococcus aureus. Semin Immunopathol. 2011; 34(2):335-48. PMC: 4184131. DOI: 10.1007/s00281-011-0293-5. View

16.

Durai R, Ng P, Hoque H . Methicillin-resistant Staphylococcus aureus: an update. AORN J. 2010; 91(5):599-606. DOI: 10.1016/j.aorn.2009.11.065. View

17.

Fattom A, Sarwar J, Ortiz A, Naso R . A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun. 1996; 64(5):1659-65. PMC: 173976. DOI: 10.1128/iai.64.5.1659-1665.1996. View

18.

Liang X, Ji Y . Alpha-toxin interferes with integrin-mediated adhesion and internalization of Staphylococcus aureus by epithelial cells. Cell Microbiol. 2006; 8(10):1656-68. DOI: 10.1111/j.1462-5822.2006.00740.x. View

19.

Maira-Litran T, Kropec A, Goldmann D, Pier G . Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun. 2005; 73(10):6752-62. PMC: 1230901. DOI: 10.1128/IAI.73.10.6752-6762.2005. View

20.

Josefsson E, Hartford O, OBrien L, Patti J, Foster T . Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis. 2001; 184(12):1572-80. DOI: 10.1086/324430. View